'What Is Microbiologic Success?': Rare Lung Infection Is Microcosm Of Antibiotic Development Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is working hard on expanded access program for patients with non-tuberculous mycobacterial (NTM) lung infections; there is no approved drug for the condition in part because of the difficulty in defining trial endpoints.
You may also be interested in...
Insmed’s Amikacin Faces US FDA Questions On Surrogate Endpoint, Target Population
Amikacin liposome inhalation suspension seeking accelerated approval to treat nontubercuolous mycobacterial lung disease caused by Mycobacterium avium complex in adults but has only studied patients with refractory disease; agency also wants its advisory committee to opine on confirmatory trial design.
Insmed Phase III Date Support Accelerated Approval For ALIS In Rare Lung Disease
Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in a Phase III study of adult patients with a rare, bacteria-driven lung disease.
ALIS In Wonderland: Insmed Reaches Fairy Tale Heights On Lung Disease Results
Insmed will commercialize ALIS, its inhaled amikaycin formerly known as Arikayce, on its own for a rare, bacteria-driven lung disease if the company can win accelerated approval based on new Phase III results.